Is Procter & Gamble a Buy After Its Latest Earnings Report?

Procter & Gamble's stock surged over 5% following stronger-than-expected organic sales growth of 4% in Q1 FY2027, driven primarily by volume and product mix improvements rather than price increases. However, earnings growth remains sluggish with core EPS increasing only 1%, as the company faces persistent margin pressures from higher commodity costs and tariffs. With P&G now trading at 23.5x forward earnings (up from 21x earlier in the year), the analyst suggests waiting for a more favorable entry point, as the stock would need significant earnings acceleration and multiple expansion to deliver compelling 10% annualized returns over the next five years.